Board Member

Board Members

Philip Davy: President & CEO

Experimental Officer at Covance (CRO, UK), Graduate Assistant and Junior Researcher at the University of Hawaii, joined Braizon in 2018, Senior Scientist, General Manager of Business Development Department, Head of Global Business Development in 2021, President and CEO of U.S. Subsidiary In September 2022, President and CEO in 2022 Sep. 

a Bachelor of Science in Chemistry from St. Andrews University, a Master of Science in Environmental Microbiology from the University of Aberdeen, and a University of Hawaii Molecular Biological Science and Engineering (Ph.D., Science).

Hiromichi Kimura : Board Member

After working at the pharmaceutical division of Kyowa Hakko Kogyo and J.P. Morgan as Vice President, Mergers & Acquisitions Division, Dr. Kimura became President and Representative Director of Amersham Pharmacia Biotech KK (present: GE Healthcare Japan), Monsanto Japan Ltd. (present: Pfizer Japan Inc.), and subsequently CEO of HuBit Genomix Inc.
In March 2004, Dr. Kimura co-founded Fast Track Initiative (FTI) Inc. and became President of the partnership.
Graduated from the faculty of pharmaceutical sciences, the University of Tokyo.
Ph.D. in pharmaceutical sciences from the University of Tokyo
Doctor of Pharmacy
MBA from the Graduate School of Business, Stanford University

Tomohiro Anzai : Board Member

Dr. Anzai joined Arthur D. Little (Japan) Inc. where he was engaged in management consulting for biotechnology businesses both inside and outside Japan. He dealt with business challenges for a wide range of companies in the fields of life sciences and health care, including pharmaceutical manufacturers, diagnostic pharmaceuticals manufacturers, equipment for research and development/reagent manufactures, and food manufacturers. He was also involved in R&D and business strategy development, focusing on company-wide strategic planning and implementation support. In January 2006, Dr. Anzai joined FTI Inc. and has been in charge of various areas, from selecting investment projects, to founding and developing companies, and investment recovery.
Graduated from the Department of Biological Sciences, Faculty of Science, the University of Tokyo
Ph.D. in molecular biology from the Graduate School of Frontier Sciences, the University of Tokyo
Special researcher of the Japan Society for the Promotion of Science
Doctor of Life Science

Mikio Kawahara : Board Member

Since 2016, Mr. Mikio Kawahara has been Head of Investment and Business Development at UTokyo Innovation Platform Co., Ltd. (UTokyo IPC), the University of Tokyo’s investment arm for innovations and start-ups.
Before joining UTokyo IPC, Mr. Kawahara worked for Toppan Printing Co., Ltd. in 1997. At Toppan, he launched his career as a computer engineer at the firm’s research center. After moving to the Corporate Planning Division at the firm’s headquarters, he engaged in many diversified projects involving corporate restructuring, strategic alliances, and M&As. In 2007, he established Riken Genesis Co., Ltd., a new biotech start-up from RIKEN Research Institute, and led its management as Chief Operating Officer. In this role, he pioneered the personalized medicine business in Japan.
From 2014, he concurrently served as President and CEO of BNA Inc., a biotech venture incubated at Osaka University. He assumed the post of Board member at Braizon Therapeutics, Inc. in August 2018.
Master of Mathematical Engineering, Graduate School of Engineering, the University of Tokyo.
MBA, Kellogg School of Management, Northwestern University.
Master of Engineering Management, McCormick School of Engineering, Northwestern University.

Masahiro Otsu : Chief Scientific Officer

Researcher at the Laboratory of Neuroregeneration Science, Graduate School of Tokyo Metropolitan University, Assistant Professor at the Department of Chemistry, Kyorin University School of Medicine, and Marie Skłodowska-Curie at the University of Birmingham (Institute of Inflammation and Ageing, UK). Individual Research Fellow, joined the Company in 2018, Manager of R&D Department, 2023 Director of R&D Department, January 2024 Director and CSO
Aoyama Gakuin University, Faculty of Science and Engineering (BSc, Chemistry), Aoyama Gakuin University, Graduate School of Science and Engineering (MSc, Chemistry), Tokyo Metropolitan University, Graduate School of Health Sciences (PhD, Health Sciences)

Makoto Takeuchi : Corporate Auditor

Mr. Takeuchi previously spent long term at Yamanouchi Pharmaceutical Co., Ltd. and Astellas Pharma Inc. in roles of increasing responsibility in the Research Division and ultimately up to Senior Corporate Executive and Head of External Relations. He has extensive experience in industrial pharmaceutical research, especially in g inflammation and bone metabolism areas, and he was deeply involved in the discovery and launch of new medicines such as Minodronate and Solifenacin for the treatment of osteoporosis and overactive bladder, respectively. He also studied abroad at the University of Pennsylvania (Prof. Amos Smith III) for one year from 2001.
He has also worked for the Japan Pharmaceutical Manufacturers Association (JPMA) as chairman of the Pharmaceutical Industrial Policy Committee and R & D Committee, and for the Forum for Innovative Regenerative Medicine (FIRM) as a vice chairman and so on.
He graduated from the Graduate School of Medicine and Pharmaceutical Science, Toyama Medical and Pharmaceutical University. A lecturer of Forefront of Drug Discovery Seminar hosted by Foundation Pharmaceutical Council. A member of the verification committee for the National Institute of Advanced Industrial Science and Technology self-evaluation.